Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...
Studies have shown that PMN from adults and neonates exhibit heterogeneity of function and 31D8 MAb binding. The heterogenity of 31D8 binding correlates with PMN motile heterogeneity. MOI MAb binds to ...
Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.
Shareholders appeared unconcerned with Phoenix Mecano AG's (VTX:PMN) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the business are ...
BIRMINGHAM, Ala. - University of Alabama at Birmingham researchers have found a novel, previously unreported pathogenic entity that is a fundamental link between chronic inflammation and tissue ...
Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to ...
Researchers have found a novel, pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in lungs of patients with COPD. These exosomes from activated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results